| Primary |
| Benign Prostatic Hyperplasia |
14.8% |
| Drug Use For Unknown Indication |
13.6% |
| Hypertension |
11.1% |
| Diabetes Mellitus |
7.4% |
| Prostatomegaly |
4.9% |
| Renal Colic |
4.9% |
| Sciatica |
4.9% |
| Sepsis |
4.9% |
| Anxiety |
3.7% |
| Asthma |
3.7% |
| Prostatic Disorder |
3.7% |
| Constipation |
2.5% |
| Dementia |
2.5% |
| Gastritis Prophylaxis |
2.5% |
| Infection |
2.5% |
| Insomnia |
2.5% |
| Myocardial Ischaemia |
2.5% |
| Nasopharyngitis |
2.5% |
| Pain |
2.5% |
| Thrombosis |
2.5% |
|
| Confusional State |
13.5% |
| Product Substitution Issue |
10.8% |
| Cerebral Haemorrhage |
8.1% |
| Thrombocytopenia |
8.1% |
| Coma |
5.4% |
| Rash Erythematous |
5.4% |
| Renal Failure Acute |
5.4% |
| Stevens-johnson Syndrome |
5.4% |
| Sudden Death |
5.4% |
| Toxic Epidermal Necrolysis |
5.4% |
| Acute Generalised Exanthematous Pustulosis |
2.7% |
| Arrhythmia |
2.7% |
| Arthralgia |
2.7% |
| Bladder Disorder |
2.7% |
| Blood Pressure Decreased |
2.7% |
| Bone Marrow Failure |
2.7% |
| Cataract |
2.7% |
| Colon Cancer |
2.7% |
| Cytolytic Hepatitis |
2.7% |
| Dermatitis Exfoliative |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
34.8% |
| Hypertension |
13.9% |
| Benign Prostatic Hyperplasia |
9.7% |
| Drug Use For Unknown Indication |
8.6% |
| Anxiety |
4.5% |
| Diabetes Mellitus |
3.7% |
| Pain |
3.4% |
| Septic Shock |
2.2% |
| Agitation |
1.9% |
| Atrial Fibrillation |
1.9% |
| Prostatic Adenoma |
1.9% |
| Abscess |
1.5% |
| Endocarditis |
1.5% |
| Extrapyramidal Disorder |
1.5% |
| Intervertebral Discitis |
1.5% |
| Memory Impairment |
1.5% |
| Renal Colic |
1.5% |
| Schizophrenia |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
| Urinary Tract Disorder |
1.5% |
|
| Stevens-johnson Syndrome |
10.0% |
| Metabolic Alkalosis |
8.0% |
| Neutropenia |
8.0% |
| Vomiting |
8.0% |
| Orthostatic Hypotension |
6.0% |
| Renal Failure Acute |
6.0% |
| Abdominal Wall Haematoma |
4.0% |
| Cardio-respiratory Arrest |
4.0% |
| Dehydration |
4.0% |
| Drug Interaction |
4.0% |
| Epilepsy |
4.0% |
| Hypotension |
4.0% |
| Hypovolaemic Shock |
4.0% |
| Loss Of Consciousness |
4.0% |
| Pulmonary Alveolar Haemorrhage |
4.0% |
| Renal Failure |
4.0% |
| Respiratory Arrest |
4.0% |
| Toxic Epidermal Necrolysis |
4.0% |
| Tremor |
4.0% |
| Acute Generalised Exanthematous Pustulosis |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.5% |
| Drug Use For Unknown Indication |
13.1% |
| Hypertension |
10.6% |
| Benign Prostatic Hyperplasia |
4.8% |
| Atrial Fibrillation |
3.7% |
| Multiple Myeloma |
3.6% |
| Diffuse Large B-cell Lymphoma |
3.2% |
| Renal Transplant |
3.2% |
| Pain |
3.0% |
| Multiple Sclerosis |
2.9% |
| Type 2 Diabetes Mellitus |
2.6% |
| Depression |
2.6% |
| Prophylaxis |
2.6% |
| Hypercholesterolaemia |
2.4% |
| Prostate Cancer |
2.3% |
| Anxiety |
1.9% |
| Constipation |
1.8% |
| Prostatic Disorder |
1.7% |
| Rheumatoid Arthritis |
1.7% |
| Acute Coronary Syndrome |
1.7% |
|
| Withdrawal Syndrome |
7.8% |
| Pneumonia |
6.2% |
| Thrombocytopenia |
6.2% |
| Agranulocytosis |
5.4% |
| Hypotension |
5.4% |
| Myalgia |
5.4% |
| Respiratory Failure |
5.4% |
| Tremor |
5.4% |
| Urinary Retention |
5.4% |
| Drug Ineffective |
4.7% |
| Nausea |
4.7% |
| Overdose |
4.7% |
| Syncope |
4.7% |
| Tendon Rupture |
4.7% |
| Vomiting |
4.7% |
| Circulatory Collapse |
3.9% |
| Death |
3.9% |
| Dermatitis Bullous |
3.9% |
| Haemoglobin Decreased |
3.9% |
| Hepatic Enzyme Increased |
3.9% |
|
| Interacting |
| Dementia |
57.9% |
| Product Used For Unknown Indication |
28.9% |
| Benign Prostatic Hyperplasia |
2.6% |
| Hepatitis C |
2.6% |
| Organic Erectile Dysfunction |
2.6% |
| Prostatic Adenoma |
2.6% |
| Sleep Phase Rhythm Disturbance |
2.6% |
|
| Drug Interaction |
50.0% |
| Asthenia |
16.7% |
| Death |
16.7% |
| Renal Failure |
16.7% |
|
